{"url_path":"/sec/dftx/8-k/2026-06-24/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-077354-index.html","accession_number":"0001104659-26-077354","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-077354-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":139,"has_tables":true,"body_markdown":"****\n\n \n\n \n\n**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n**(d)       Exhibits**\n\n**  **\n\n**Exhibit** **No.**\n \n**Description**\n\n[1.1](tm2618395d3_ex1-1.htm)\n \n[Underwriting Agreement among Definium Therapeutics, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc., as representatives of the underwriters named therein, dated June 23, 2026.](tm2618395d3_ex1-1.htm)\n\n \n \n \n\n[5.1](tm2618395d3_ex5-1.htm)\n \n[Opinion of Osler, Hoskin & Harcourt LLP.](tm2618395d3_ex5-1.htm)\n\n \n \n \n\n[23.1](tm2618395d3_ex5-1.htm)\n \n[Consent of Osler, Hoskin & Harcourt LLP (included in Exhibit 5.1).](tm2618395d3_ex5-1.htm)\n\n \n \n \n\n[99.1](tm2618395d3_ex99-1.htm)\n \n[Press Release, dated June 22, 2026.](tm2618395d3_ex99-1.htm)\n\n \n \n \n\n[99.2](tm2618395d3_ex99-2.htm)\n \n[Press Release, dated June 23, 2026.](tm2618395d3_ex99-2.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.\n\n \n\n \nDEFINIUM THERAPEUTICS, INC.\n\n \n \n \n\nDate: June 24, 2026\nBy:\n/s/ Robert Barrow\n\n \nName:\nRobert Barrow\n\n \nTitle:\nChief Executive Officer"}